AQNEURSA® (levacetylleucine) Recommended for EU Approval by the CHMP to Treat Niemann-Pick Disease Type C
AQNEURSA® could offer a new frontline treatment for NPC patients in Europe CHMP recommendation based on Phase III pivotal trial data and extension phase data, showing rapid symptomatic improvement, long-term benefit, and disease-modifying, neuroprotective effects1,2 European Commission decision will follow later this year AQNEURSA previously received U.S. FDA approval in September, 2024 AUSTIN, Texas–(BUSINESS … [Read more…]
